Reviva to present new non-clinical pharmacology data on brilaroxazine at the aspet 2024 annual meeting

Cupertino, calif., may 09, 2024 (globe newswire) -- reviva pharmaceuticals holdings, inc. (nasdaq: rvph) (“reviva” or the “company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (cns), inflammatory and cardiometabolic diseases, today announced that laxminarayan bhat, ph.d., founder, president, and ceo of reviva will present new pharmacology data on brilaroxazine as part of two poster presentations at the aspet 2024 annual meeting, to be held in arlington, va may 16-19, 2024.
RVPH Ratings Summary
RVPH Quant Ranking